GlassScriptPhysician profile
Hitesh Makkar
NPI 1184693046
$5,349.27
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $500 · 2021: $1,407 · 2022: $1,773 · 2023: $1,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,050.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $937.25 | 2019-2023 | Nucala |
| Inspire Medical Systems, INC. | $684.42 | 2021-2023 | Inspire |
| Astrazeneca Pharmaceuticals LP | $518.37 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $325.96 | 2020-2023 | Acthar |
| Jazz Pharmaceuticals INC. | $319.73 | 2019-2023 | |
| United Therapeutics Corporation | $309.65 | 2019-2023 | Tyvaso, Orenitram |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.83 | 2019-2023 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genzyme Corporation | $212.12 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $169.10 | 2019-2023 | Opsumit |
| Regeneron Healthcare Solutions, INC. | $151.65 | 2021-2023 | Dupixent |
| Amgen INC. | $141.03 | 2020-2023 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $125.43 | 2021-2023 | |
| Harmony Biosciences LLC | $116.34 | 2021 | |
| Genentech USA, INC. | $107.83 | 2019-2023 | Xolair |
| Sanofi-Aventis U.S. LLC | $81.99 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hitesh Makkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.